Market accessOfficial

Estonia's medicines agency publishes 2026 statistical yearbook covering 2021–2025 market and use trends

🇪🇪 Ravimiamet · Tue 17 Nov 2026

Ravimiamet's yearbook reports semaglutide use rising from 2.9 to 21.6 DDD per 1,000 inhabitants daily and ADHD medicine use quadrupling, alongside a €559m wholesale market.

The Estonian State Agency of Medicines (Ravimiamet) has published its Statistical Yearbook 2026, an overview of the country's medicines market, medicines use and pharmacy activity from 2021 to 2025. The publication is a data resource and does not introduce regulatory requirements or safety actions.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: Ravimiamet ↗

Article written by VigiEye from the official source (Ravimiamet). AI-assisted; check the source before acting.